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Coxiella burnetii is a category B bioterrorism agent. We 
numerically evaluated the risks and beneﬁ  ts from postex-
posure prophylaxis (PEP) after an intentional release of C. 
burnetii to the general population, pregnant women, and 
other high-risk populations. For each group, we constructed 
a decision tree to estimate illness and deaths averted by 
use of PEP/100,000 population. We calculated the thresh-
old points at which the number of PEP-related adverse 
events was equal to the cases averted. PEP was deﬁ  ned 
as doxycycline (100 mg 2×/day for 5 days), except for preg-
nant women, where we assumed a PEP of trimethoprim-
sulfamethoxazole (160 mg/800 mg 2×/day) for the duration 
of the pregnancy. PEP would begin 8–12 days postexpo-
sure. On the basis of upper-bound probability estimates of 
PEP-related adverse events for doxycycline, we concluded 
that the risk for Q fever illness outweighs the risk for anti-
microbial drug–related adverse events when the probabil-
ity of C. burnetii exposure is >7% (pregnant women using 
trimethoprim-sulfamethoxazole = 16%).   
Q 
fever is caused by the intracellular bacterium Coxiella 
burnetii and is endemic in nearly every country in the 
world. A zoonotic disease, it is usually transmitted to hu-
mans through aerosolization of the bacteria from animal 
products; person-to-person transmission is rare (1–4). 
Roughly 50% of all C. burnetii human infections are 
asymptomatic (5–8). Acute illness is usually characterized 
by sudden onset febrile illness; chronic disease occurs in 
≈1% of all acute cases with endocarditis being the most 
common chronic condition (60%–70%) (1,8–12). Persons 
with preexisting cardiac valve defects are at signiﬁ  cantly 
higher risk for chronic disease; chronic disease develops in 
39% of patients treated for acute disease (in 75% without 
treatment) (13–15). Immunocompromised patients (e.g., 
HIV-positive and cancer patients) are also at increased risk 
for chronic illness. 
A Q fever–associated chronic fatigue syndrome may 
exist as well. Although prevalence is controversial, studies 
have cited that 10%–30% of all patients with acute disease 
report persistent symptoms (e.g., fatigue, myalgia, night 
sweats) more than a year after acute infection occurred 
(10,16). Pregnant women are also at increased risk for se-
vere acute C. burnetii infection because of the bacterium’s 
predilection for the placenta. Premature birth (33%) and 
spontaneous abortion/neonatal deaths (39%) occur fre-
quently in acutely ill pregnant women (17). 
C. burnetii is classiﬁ  ed as a category B bioterrorism 
agent by the Centers for Disease Control and Prevention 
and the National Center for Allergy and Infectious Dis-
eases (18). Regardless of the likelihood that C. burnetii 
may be used as a bioterrorism agent due to its status as a 
category B agent, public health agencies are obligated to 
prepare for such a scenario. Current Q fever postexposure 
prophylaxis (PEP) guidelines for the general population are 
100 mg of doxycycline (or 500 mg tetracycline 2×/day for 
5 days), started 8–12 days postexposure (4). This recom-
mendation is based on limited studies conducted at Fort 
Detrick, Maryland, USA in the 1950s, which indicated that 
administering antimicrobial drugs directly after exposure 
to C. burnetii extended the incubation period by 8–10 days 
but did not prevent infection from occurring (19). Waiting 
8–12 days after exposure before starting treatment prevent-
ed illness (19).    Unfortunately, these guidelines do not 
account for the probability of exposure and prophylaxis-
related adverse events. Also, the US government has not 
published any PEP recommendations for pregnant women, 
although trimethoprim-sulfamethoxazole (TMP-SMX) has 
been suggested as a possibility (1,4). 
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To assist in the development of PEP recommendations, 
we present a risk-beneﬁ  t analysis, estimating the number of 
cases of illness/death that could be averted with PEP after 
a large release of Q fever versus a treatment-only strate-
gy where antimicrobial drugs are administered only upon 
symptom onset. We also determine the threshold probabil-
ity of exposure at which the risk for antimicrobial-related 
adverse events outweighs the risk for Q fever illness.
Methods
Model  
In 2006, we conducted a risk-beneﬁ  t analysis for each 
of the following groups: the general population, high-risk 
populations (persons with valvular defects or heart prob-
lems and the immunocompromised), and pregnant women. 
Total medical outcomes averted for each group were calcu-
lated by using the following general equation:
Total medical cases averted = (Total adverse health out-
comes caused by Q fever without PEP) – (total adverse 
health outcomes caused by Q fever remaining after in-
tervention) – (cases of PEP-related adverse events)
The online Technical Appendix (available from www.cdc.
gov/EID/content/14/10/1558-Techapp.pdf) contains the 
equations deﬁ  ning each input (e.g., total adverse outcomes 
without PEP) of this equation.
To calculate adverse outcomes with and without PEP, 
we constructed a decision tree for each target group illus-
trating all possible outcomes after exposure to C. burnetii. 
The general population and high-risk populations share 
the same tree structure (Figures 1, 2); the tree for pregnant 
women incorporates the outcomes for the unborn child (Fig-
ure 3). Drug-related side effects are not included in Figures 
1–3; however, the number of side effects was calculated 
per Equation 4 in the online Technical Appendix. Total 
medical cases averted were calculated at 4 arbitrary levels 
of C. burnetii exposure (100%, 50%, 25%, and 10%). 
Cohort Size and Discounting 
We assumed a cohort of 100,000 for each model. Also, 
given that each exposed patient would begin to fully expe-
rience any adverse health outcome from either Q fever or 
PEP within 1 year, we did not discount outcomes.
Assumptions 
Several assumptions were made in conducting this 
risk-beneﬁ  t analysis. For simplicity’s sake, 100% compli-
ance was assumed for persons receiving PEP. Risk-beneﬁ  t 
analyses are based on an aerosolized, point source, overt at-
tack, for which response can begin almost immediately. Es-
timates of cases and cases averted are based on the assump-
tion that persons in whom acute or chronic illness develops 
receive appropriate treatment and care once a diagnosis of 
Q fever has been made. Those exposed received the same 
dose of C. burnetii. Although limited studies have shown 
an increase in dose can decrease the incubation period of 
the disease and/or increase the severity of illness, we were 
concerned with preventing illness all together (9,20). 
Because Q fever has a low infectious dose (a single 
spore/bacterium may be enough to cause illness) (19), we 
assumed any dose would be sufﬁ  cient to cause clinical in-
fection. PEP does not affect the course or severity of illness 
in persons who become ill after having received prophy-
lactic antibimicrobial drugs (persons in the PEP and no-
PEP groups have the same probability of outcome events 
occurring once acute illness developed); persons in the No 
Illness group are assumed to have no latent illness. 
Interventions 
Our analyses considered 2 different PEP options. For 
the general and high-risk populations, we assumed a PEP 
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Figure 1. Decision tree for a general population of 100,000 based 
on an assumption of an aerosolized, point source, overt attack 
with  Coxiella burnetii (postexposure prophylaxis [PEP] with 100 
mg doxycycline 2×/d for 5 d, assuming 82% drug efﬁ  cacy  and 
100% exposure). PEP-related adverse events are not included 
in this ﬁ   gure. The probability of each individual event occurring 
is provided in the decision tree under the respective event title 
(i.e., 1.00 for Exposure). Some events list a range of probabilities 
with the speciﬁ  c probability for this scenario in parentheses (i.e., 
0.82–0.965 (0.82) for PEP No illness). The number of persons 
with each respective outcome is listed on the right side of the tree. 
A summary of outcomes (total illness, severe illness, and death) 
and the percentage of the population with such an outcome are 
provided in the table below the PEP and No PEP trees. We deﬁ  ned 
total illness as all acute illness, severe illness, and Q fever–related 
deaths. Severe illness was deﬁ  ned as hospitalization during acute 
infection, chronic illness, Q fever fatigue syndrome (QFS), or death. 
This description also applies to Figures 2 and 3.RESEARCH
dosage of 100 mg of doxycycline 2×/day for 5 days, begin-
ning 8–12 days postexposure. As doxycycline is generally 
not recommended for pregnant women, we assumed a PEP 
dosage of 160 mg/800 mg TMP-SMX 2×/day for the dura-
tion of the pregnancy, starting 8–12 days postexposure (21).
Q Fever–related Outcomes
To provide some sense of risk-by-severity of out-
come, we categorized health outcomes into 3 cumulative 
categories: total illness, severe illness, and death. We de-
ﬁ  ned total illness as all acute illness, severe illness, and Q 
fever–related deaths. Severe illness includes hospitaliza-
tion during acute infection, chronic illness, Q fever fatigue 
syndrome (QFS), and death. For pregnant women, the out-
come of the unborn child is included in illness estimates: 
low-birthweight newborns were included in the total illness 
estimates, and abortions/newborn deaths were included in 
all 3 outcome categories.
We provide, in Table 1, the values used in the analy-
ses based on information we obtained from an extensive 
literature review. The probabilities associated with each 
possible event were multiplied and applied to a population 
of 100,000 to estimate the number of people who would 
experience a given outcome with and without PEP (Figures 
1–3). Cases averted because of PEP use were calculated 
(Equation 4 in online Technical Appendix). 
PEP-related Adverse Events
The medical literature was reviewed to determine the 
probabilities of adverse events associated with doxycycline 
and trimethoprim-sulfamethoxazole. Adverse events were 
categorized as moderate, severe, or death resulting from 
prophylactic antibimicrobial drug use. We assumed that 
a moderate PEP-related adverse event is equivalent to an 
acute case of Q fever, a severe PEP-related adverse event is 
equivalent to a severe acute case or chronic case of Q fever, 
and a death from PEP use is equal to a death from Q fever.
A best estimate and an upper bound estimate for the 
probabilities of adverse events were selected (Table 2). 
The best estimates for rates of adverse events from doxy-
cycline are based on estimates cited in a study of anthrax 
prophylaxis–related adverse events (for both doxycycline 
and ciproﬂ  oxacin) (33). The upper bound estimates for 
doxycycline are arbitrarily deﬁ  ned as 3× the best estimate 
probabilities. In the case of the upper bound probability of 
death for doxycycline, because a death rate of 0.0% was 
stated in the literature (30,33), 0.01% was arbitrarily as-
signed on the basis of the best estimate for severe adverse 
events (0.01%). 
The best estimate for moderate adverse events from 
TMP-SMX is based on a study that cited 3.9% (7/180) of 
patients discontinued antimicrobial drug treatment based on 
adverse events (34). Two other studies reported that 11% of 
patients prematurely discontinued TMP-SMX use based on 
adverse events (24,35). However, these studies likely over 
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Figure 2. Decision tree for a high-risk population of 100,000 based 
on an assumption of an aerosolized, point source, overt attack with 
Coxiella burnetii (postexposure prophylaxis [PEP] with 100 mg 
doxycycline 2×/d for 5 d, assuming 82% drug efﬁ  cacy and 100% 
exposure). PEP-related adverse events are not included in this 
ﬁ  gure. QFS, Q fever fatigue syndrome.
Figure 3. Decision tree for 100,000 pregnant women based on 
an assumption of an aerosolized, point source, overt attack with 
Coxiella burnetii (postexposure prophylaxis [PEP] with 160/800 mg 
trimethoprim-sulfamethoxazole 2×/d for duration of pregnancy, 
assuming 82% efﬁ  cacy and 100% exposure.) PEP-related adverse 
events are not included in this ﬁ  gure. The “No PEP” segment of the 
tree contains the same branches and nodes as seen in the “With 
PEP” section, but uses different probabilities for certain variables. 
*The outcome of the unborn child is included in pregnant women 
illness estimates: low birth weight newborns were included in “Total 
Illness” estimates, and abortions/newborn deaths were included in 
all 3 outcome categories. QFS, Q fever fatigue syndrome.
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estimate the probability of moderate AEs as some patients 
may discontinue use after experiencing only mild adverse 
events. Therefore, the lowest percent cited in the literature 
(3.9%) was used as the best estimate, and 11% was set as 
the upper bound estimate. We note that this best estimate 
may still be an overestimate.
A probability of 0.00037% was selected for the ad-
verse deaths from TMP-SMX use, which is derived from a 
study that estimated 3.7 deaths/million treatments (36). We 
assumed that most deaths from TMP-SMX treatment are a 
result of toxic epidermal necrolysis (TEN) (37). A severe 
adverse event probability of 0.00123% is based on the esti-
mate that 30% of TEN cases result in death (37). 
As stated above, the TMP-SMX upper bound estimate 
for moderate adverse events was set at 11% (24,35). The 
TMP-SMX upper bound severe AE estimate, 0.0037%, 
was obtained by multiplying the TMP-SMX best estimate 
for severe AEs by 3. This was done to remain consistent 
with the arbitrary selection of an upper bound severe ad-
verse event estimate for doxycycline, which used the same 
selection technique. Lastly, 0.0011% was used as the upper 
bound estimate for TMP-SMX-related deaths on the basis 
of the aforementioned assumption that 30% of severe ad-
verse events (i.e., TEN) result in death (37). Because of 
lack of relevant data, and to avoid underestimating drug-
related side effects, we assumed the upper bound estimate 
of doxycycline-related deaths to be ≈10× greater than that 
of TMP-SMX (Table 2).
Threshold Point
The threshold point is deﬁ  ned as the probability of 
exposure to C. burnetii where the number of PEP-related 
adverse events equals the cases averted because of PEP 
use. The risk for adverse events equals the beneﬁ  t of PEP 
use. 
Sensitivity Analyses
We conducted initial sensitivity analyses on the ef-
ﬁ  cacy of doxycycline (96.5% and 82%) and TMP-SMX 
(96.5%, 82%, and 40%). These drug efﬁ  cacies were cho-
sen on the basis of a review of the literature (Table 1; on-
line Appendix Table 1, available from www.cdc.gov/EID/
content/14/10/1558-appT1.htm), but because of lack of ev-
idence of TMP-SMX’s efﬁ  cacy as a prophylaxis for Q fe-
ver, we arbitrarily chose a low-range efﬁ  cacy value (40%). 
Because of uncertainty in many of the input values for the 
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Table 1. Input values used in the primary and secondary analyses of PEP efficacy* 
Sensitivity analyses 
Variable
Primary analysis 
(sensitivity analysis)  Less virulent  More virulent  References
Exposure (0.10, 0.25, 0.50, 1.00) NA NA NA
Efficacy of doxycycline PEP (8–12 d 
postexposure)
0.82 (0.82–0.965) 0.965 0.40 (22,23)
Efficacy of trimethoprim-sulfamethoxazole PEP 
(8–12 d postexposure)
0.82 (0.40–0.965) 0.965 0.40 (21,24,25)
Asymptomatic infection w/o PEP (all groups) 0.50 0.65 0.40 (1,3,5,7,8,26)
Full recovery after acute (gp) 0.74 Residual (0.934) Residual (0.576) (7–9)
Full recovery after acute illness (hr) 0.28 Residual (0.739) Residual (0.076) (7–9)
Full recovery after acute illness (pw) 0.08 Residual (0.57) Residual (0.02) (7–9)
Probability of hospitalization and recovery given 
acute illness (gp)
0.04 0.01 0.05 (5,7,27)
Probability of hospitalization and recovery given 
acute illness (hr)
0.01 0.01 0.05 (5,7)
Probability of hospitalization and recovery given 
acute illness (pw)
0.01 0.01 0.02 (5,7)
Q fever fatigue syndrome (gp) 0.20 0.05 0.30 (1,10,16,28–30)
Q fever fatigue syndrome (hr) 0.30 0.05 0.20 (1,10,16,28–30)
Q fever fatigue syndrome (pw) 0.03 Residual (0.03) Residual (0.04) (1,10,16,17,28–30)
Death from acute illness (gp) 0.01 0.001 0.024 (7,9–11)
Death from acute illness (hr and pw) 0.02 0.001 0.024 (7,9–11)
Chronic disease (gp) 0.01 0.005 0.05 (8,11,12,26,31)
Chronic disease (hr) 0.39 0.20 0.65 (13,14,31)
Chronic disease (pw) 0.86 0.39 0.90 (17)
Endocarditis (all groups) 0.65 0.60 0.90 (1,7,8)
Death from endocarditis (all groups) 0.10 0.05 0.60 (1,3,7,8,11,15,32)
Death from other chronic diseases (all groups)  0.30 0.05 0.60 (9)
Abortion or neonatal death 0.38 0.25 0.56 (8,14 ,17,21)
Premature birth/low birth weight baby 0.33 0.25 0.28 (8,14,17,21)
Healthy, unaffected baby 0.29 0.50 0.16 (8,14,17,21)
*PEP, postexposure prophylaxis; NA, not applicable; gp, general population; hr, high-risk; pw, pregnant women. See online Appendix Table 1 (available 
from www.cdc.gov/EID/content/14/10/1558-appT1.htm) for a detailed explanation of how the primary input values were selected. RESEARCH
primary analyses (Table 1), we conducted 2 additional sce-
narios labeled less virulent and more virulent. “Less viru-
lent” and “more virulent” are the terms used to describe the 
lower and upper bound of the sensitivity analyses. The less 
virulent values are those that create a best-case scenario for 
health outcomes, while the more virulent analysis uses the 
worst-case scenario values.
As appropriate, we reduced (for less virulent) or in-
creased (for more virulent) the input values used in the pri-
mary scenario (Table 1; online Appendix Table 1). In many 
instances, we did not have reliable measures to deﬁ  ne less 
or more virulence and values were assumed as needed. As 
before, we ran each of the altered virulence scenarios as-
suming different levels of drug efﬁ  cacy (doxycycline, 82% 
and 96.5%; TMP-SMX, 40%, 82%, and 96.5%).
Results
We estimate that without the use of postexposure pro-
phylaxis, exposing a general population of 100,000 to C. 
burnetii would result in 50,000 cases of illness, 13,000 
severe cases, and 585 deaths (Figure 1). Figures 2 and 3 
provide results for the high-risk population and pregnant 
women, respectively. If we assume 82% drug efﬁ  cacy for 
doxycycline, 9,000 cases of illness, 2,340 severe cases, and 
105 deaths would occur within an exposed general popula-
tion that took PEP. This translates to 41,000 cases of ill-
ness, 10,660 severe cases, and 480 deaths averted because 
of PEP use (82% reduction of cases). In addition, using 
doxycycline as PEP in a population of 100,000 (using the 
adverse event best estimates found in Table 2) would re-
sult in ≈1,010 moderate adverse events, 10 severe adverse 
events, and 0 deaths. Therefore, subtracting these adverse 
events from the total PEP-averted cases show that PEP use 
in this population would prevent 39,990 cases of total ill-
ness, 10,650 severe cases, and 480 deaths. Table 3 displays 
the total medical cases averted (accounting for PEP-related 
adverse events) for each group.
Figures 1–3 also include the percentage of each popula-
tion that would develop illness/death with and without the 
use of PEP. Of particular importance is the probability of 
severe cases of illness without PEP use; 13% of the gen-
eral population, 36% of the high-risk population, and 46% 
of pregnant women would experience severe illness. Of all 
cases of illness among the general population, the high-risk 
population and pregnant women, 26%, 72%, and 92%, re-
spectively, would be severe. Moreover, abortion or newborn 
death would occur in 19% of exposed pregnant women; 
16.5% would give birth to a low-birthweight baby. 
The threshold point is deﬁ  ned as the probability of 
exposure to C. burnetii where the risk for adverse events 
equals the beneﬁ  t of PEP use. Figure 4 illustrates the 
general population threshold points (run at 2 different 
drug efﬁ  cacy values) for total cases of illness averted for 
the primary, less, and more virulent scenarios. The x-
intercept on these graphs is the probability of exposure 
to C. burnetii at which the total number of cases of ill-
ness averted because of PEP use is equal to the number of 
moderate PEP-related adverse events. Therefore, for any 
probability of exposure greater than the stated threshold 
value, PEP would prevent more cases of illness than the 
number of adverse events PEP would cause. As Figure 
4 illustrates, the less virulent or more virulent scenarios 
affect the estimated number of cases but do not greatly 
affect the threshold probabilities of exposure. For further 
analyses, refer to online Appendix Tables 2 (available 
from www.cdc.gov/EID/content/14/10/1558-appT2.htm), 
3 (available from www.cdc.gov/EID/content/14/10/1558-
appT3.htm), and 4 (available from www.cdc.gov/EID/
content/14/10/1558-appT4.htm) to review univariate sen-
sitivity analyses on various variables used in the risk/ben-
eﬁ  t scenarios. These tables show which variables have the 
greatest independent inﬂ  uence on the respective outcomes 
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Table 2. Probability of adverse events associated with postexposure prophylactic antimicrobial agents 
Doxycycline* Trimethoprim-sulfamethoxazole†
Level of adverse event Best estimate Upper bound† Best estimate Upper bound
Moderate 1.01% 3.03% 3.90% 11%
Severe 0.01% 0.03% 0.00123% 0.00370%‡
Death 0.00% 0.01% 0.00037% 0.00111%
*Recommended for the general population and high-risk populations based on estimated use of 100 mg orally 2×/d for 5 d. 
†Recommended for pregnant women based on 160 mg/800 mg orally 2×/d for the duration of the pregnancy. 
‡Arbitrary upper-bound, 3× best estimate (see text for further details). 
Table 3. Total medical cases averted because of postexposure 
prophylaxis* 
Population No. cases averted
General population
All cases of illness 39,990
Severe illness 10,650
Deaths 480
High-risk population
All cases of illness 39,990
Severe illness 29,510
Deaths 3,538
Pregnant women†
All cases of illness 66,210
Severe illness 53,300
Deaths 22,394
*Accounting for best estimate drug-related adverse events, 82% drug 
efficacy, and 100% exposure. 
†Includes the outcome of the unborn child. Prophylaxis for Coxiella burnetii
and how modiﬁ  cations to the input values impacts the es-
timated number of cases averted.
Table 4 displays all threshold points by group, out-
come, drug efﬁ  cacy, and probability of an adverse event 
(best or upper bound estimate). Threshold points (when 
using primary analysis input values) range from 0.0% to 
7.4% for the general population and high-risk groups; the 
threshold points for pregnant women range from 0.001% 
to 32.2%. 
Discussion 
Based on this study, we believe many cases of illness 
and deaths could be prevented with the use of PEP after 
a deliberate, overt release of C. burnetii. Without taking 
social or political concerns into account, a threshold point 
can be interpreted as the decision point for PEP use. Any 
value above the threshold point indicates that the beneﬁ  ts 
of PEP use outweigh the risks for adverse events, therefore 
implying PEP should be recommended for any probability 
of exposure to C. burnetii above the stated threshold point. 
For the general and high-risk population, when doxycy-
cline is used as a postexposure prophylactic antimicrobial 
drug, due to low rates of AE, the argument to administer 
PEP in most cases of potential exposure is strong. Even in 
the worst case scenario (upper bound adverse event esti-
mate), the threshold point for total illness is relatively low 
at 7.4%. 
Use of TMP-SMX for pregnant women also favors 
PEP use in most scenarios. Due to higher rates of moder-
ate adverse events among TMP-SMX users, the threshold 
point for total illness is not as low as seen for doxycycline 
users (the general population and high-risk populations), 
but TMP-SMX threshold points still exhibit the importance 
of providing prophylaxis. Although the upper bound AE 
estimate in conjunction with the lower bound estimate of 
drug efﬁ  cacy (40%) indicates 32.2% is the threshold point 
for total illness, this is the worst case scenario. Both the 
upper bound estimate for adverse events and the upper 
bound drug efﬁ  cacy are considered to be overestimations 
to the preferred best estimate. The efﬁ  cacy of TMP-SMX 
as a form of PEP is likely closer to 82% on the basis of 
its efﬁ  cacy as a prophylaxis for several infections such as 
toxoplasmosis and Pneumocystis carinii pneumonia (25). 
Moreover, because Q fever is primarily an incapacitating 
agent, severe illness is likely a good proxy for the disease’s 
effects on a population. Therefore, the severe case threshold 
point (assuming 82% drug efﬁ  cacy) is low, lying between 
0.002% and 0.007% for pregnant women, which provides 
strong support for PEP use in most cases where exposure 
is suspected.
On the basis of these analyses, we determined there are 
2 variables that most strongly inﬂ  uence the model. First, 
the efﬁ  cacy of the drug as prophylaxis for Q fever is 1 of 
the most important variables in this model. Understand-
ably, if the antimicrobial agent is effective, considerable 
illness and death will be prevented. Unfortunately, there 
are limited data on the efﬁ  cacy of these drugs at preventing 
Q fever illness. Sensitivity analysis was conducted on this 
variable to account for this uncertainty; however, based on 
treatment experiences with these drugs (doxycycline’s ef-
ﬁ  cacy ranges from 82% to 99% for Chlamydia trachomatis 
cervicitis) (22,23), we think the best estimates used in this 
study (82%) are conservatively close to the actual drug ef-
ﬁ  cacies. A second important variable in the model is the 
probability of PEP-related adverse events. Once again, at-
tempts were made to account for limited data by providing 
best and upper bound estimates for adverse events.
Although this risk-beneﬁ  t analysis may be very use-
ful when developing policy and ofﬁ  cial PEP recommen-
dations, there are limitations to this design, such as some 
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Figure 4. Cases of illness averted in the general population after 
Coxiella burnetii exposure with the use of postexposure prophylaxis 
while accounting for a 1.0% probability of adverse events, broken 
down by virulence scenario and drug efﬁ  cacy. The “best estimate” 
scenario (primary analysis, A) uses best estimate input values, 
the “less virulent” scenario (B) uses input values that result in the 
least harmful outcome, the “more virulent” scenario (C) applies 
input values that result in the most harmful outcome or worst-case 
scenario. Drug efﬁ  cacy refers to the efﬁ  cacy of doxycycline as a 
post-exposure prophylaxis against C. burnetii infection. Analyses for 
doxycycline (used by the general and high-risk populations) were 
run at 2 potential drug efﬁ  cacies: 96.5% and 82%. The threshold 
points, the probability of exposure where the risk of adverse events 
equals the risk of illness, are noted on the graphs.RESEARCH
of the data on which this analysis is based. Particularly, 
the recommendation that PEP should be administered 8–12 
days postexposure is based on a single study conducted on 
only 5 persons and 1 type of antimicrobial drug (oxytetra-
cycline). We acknowledge that these are limited data, but 
administration 8–12 days postexposure still remains the of-
ﬁ  cial recommendation of the US Army Medical Research 
Institute of Infectious Diseases. As a result, we remain 
consistent with current recommendations, but we are open 
to alternative options if more evidence becomes available. 
Conducting further animal studies would help to clarify the 
optimal time and duration of drug administration and the 
ideal antimicrobial drug. Newer drugs are now available 
and these may be more effective at preventing illness. 
Another limiting variable was the death rate from acute 
Q fever infection among non-PEP users. Our study assumed 
that all persons in whom acute or chronic illness develops 
are assumed to receive appropriate treatment and care for 
the duration of illness once a diagnosis of Q fever has been 
made. Although no estimates are available in the literature 
for the death rate among treated persons (only untreated), 
we chose to use the death rate for untreated persons (1%). 
However, because of the uncertainty of this value, sensitiv-
ity analyses were conducted to assess variable effect on the 
number of severe cases of illness averted. Online Appendix 
Table 4 shows how the change in input values for both the 
PEP and no PEP groups does not greatly impact the total 
number of severe cases of illness averted within the general 
population.
Also, as mentioned before, this risk-beneﬁ  t analysis 
is based on several assumptions, such as an overt attack, 
100% exposure, and 100% compliance of the entire study 
population. These assumptions simplify the situation and 
create a more quantiﬁ  able, but more unnatural, scenario. 
Although an overt attack is less likely to occur, future 
models can adjust this assumption to account for a delay 
in diagnosis or outbreak detection. Prophylactic efﬁ  cacy 
and ultimately the number of illnesses/deaths could vary 
depending on such factors as compliance and the number of 
organisms to which the person was exposed. Another limi-
tation to acknowledge is that C. burnetii is very resilient in 
the environment and exposure a long time after the initial 
dispersal could be an issue. Our model has only accounted 
for a single-exposure event, but future models should ad-
dress this point.
Several issues will also be important when considering 
PEP recommendations. First, when selecting a representa-
tive threshold value for each risk group, social and political 
concerns must be acknowledged and considered. If a thresh-
old value is 2.5%, it may be more realistic for decision mak-
ers to instruct all persons with any probability of exposure 
to take PEP rather than use valuable time and resources to 
determine a person’s numerical probability of exposure. In 
addition, before providing a speciﬁ  c numeric threshold value 
in the guidelines, knowing how to measure that probability 
of exposure is important. For example, if 7% is provided 
as a threshold, there must be a mechanism for differentiat-
ing between 6% and 8% or 5% and 15%. These threshold 
points and PEP recommendations must be useful and real-
istic. Some research has been conducted to evaluate how to 
determine likely concentrations of a bioterrorism agent and a 
person’s level of exposure by using computer modeling and 
simulation (38). Further studies on the assessment of expo-
sure would be beneﬁ  cial; modeling Q fever exposure would 
be especially critical given C. burnetii’s low infectious dose 
and high environmental stability (9). 
Also, this study does not directly address children <8 
years of age. In general, this population is not at higher risk 
for illness/death from Q fever infection than the general 
population. However, risk-beneﬁ   t analyses for children 
should be conducted to provide guidance on PEP recom-
mendations for this age group. Lastly, this analysis was 
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Table 4. Summary of threshold points by group, drug efficacy, and probability of an adverse event (best estimate/upper bound 
estimate)
Drug efficacy
82%
Population 96.50% 40%* Primary analysis Less virulent More virulent
General population
All cases of illness 2.1/6.3 NA 2.5/7.4 3.88/11.65 1.98/5.94
Severe illness 0.08/0.24 NA 0.09/0.28 0.58/1.75 0.05/0.14
Death 0.00/1.8 NA 0.00/2.1 0.00/28.49 0.00/0.36
High-risk population
  All cases of illness 2.1/6.3 NA 2.5/7.4 3.88/11.65 1.98/5.94
 Severe  illness 0.03/0.09 NA 0.03/0.10 0.147/0.44 0.021/0.06
 Death 0.00/0.24 NA 0.00/0.28 0.00/3.5 0.00/0.05
Pregnant women
  All cases of illness 4.7/13.3 11.4/32.2 5.6/15.7 9.99/28.2 4.16/11.7
 Severe  illness 0.002/0.006 0.005/0.014 0.002/0.007 0.0069/0.021 0.0016/0.0047
 Death 0.001/0.004 0.003/0.010 0.002/0.005 0.0053/0.0156 0.0006/0.0019
*Doxycycline was not evaluated at 40% drug efficacy. NA, not available. Prophylaxis for Coxiella burnetii
conducted on the basis of the most frequently suggested 
prophylaxis regimens. However, other antimicrobial drugs 
should be evaluated with risk-beneﬁ  t analytic methods. 
Cost was not considered in this risk-beneﬁ  t analysis. 
Further studies are warranted to expand and support vari-
ous aspects of this analysis, including estimating the cost 
associated with the use of PEP after a deliberate release of 
C. burnetii. 
This study illustrates the importance and beneﬁ  t of 
postexposure prophylaxis in a mass-exposure scenario and 
also weighs the risk for prophylaxis-related adverse events. 
Early identiﬁ  cation of persons at increased risk for Q fever 
illness (pregnant women and high-risk populations) would 
be crucial in providing proper PEP and, in turn, preventing 
illness/death in these groups. Based on the study assump-
tions of exposure and compliance, PEP may be warranted 
and is likely to be effective at averting cases of illness and 
deaths in all 3 population groups when the probability of 
exposure to C. burnetii is above the population-speciﬁ  c 
threshold point. 
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etymologia etymologia
Coxiella [kok′′ se-el′ ə] burnetii
Etiologic agent of Q fever, named after American bacteriologist Herald Rea Cox and Australian physician Frank 
MacFarlane Burnet, who both independently isolated the bacterium in the 1930s. C. burnetii belongs in the family 
Coxiellaceae, which consists of gram-negative rods without ﬂ  agella or a capsule. The bacteria occur in ticks and 
various vertebrates, including humans.
Source: Dorland’s illustrated medical dictionary, 31st edition. Philadelphia: Saunders; 2007; American Veterinary Medical Association. 
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